Country: Canada
Language: English
Source: Health Canada
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
TEVA CANADA LIMITED
J05AR06
EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
600MG; 200MG; 300MG
TABLET
EFAVIRENZ 600MG; EMTRICITABINE 200MG; TENOFOVIR DISOPROXIL FUMARATE 300MG
ORAL
30
Prescription
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
Active ingredient group (AIG) number: 0352327001; AHFS:
APPROVED
2017-07-26
PRODUCT MONOGRAPH PR TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR Efavirenz, Emtricitabine and Tenofovir Tablets Teva Standard 600 mg/200 mg/300 mg (efavirenz/emtricitabine/tenofovir disoproxil fumarate) Antiretroviral Agent Teva Canada Limited Date of Revision: 30 Novopharm Court June 1, 2020 Toronto, Ontario Canada M1B 2K9 www.tevacanada.com Control No.: 238915 _TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR Product Monograph _ _ _ _ _ _ _ _ 2 _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................................3 INDICATIONS AND CLINICAL USE .......................................................................................3 CONTRAINDICATIONS ............................................................................................................3 WARNINGS AND PRECAUTIONS ...........................................................................................4 ADVERSE REACTIONS ...........................................................................................................15 DRUG INTERACTIONS ...........................................................................................................23 DOSAGE AND ADMINISTRATION .......................................................................................39 OVERDOSAGE .........................................................................................................................39 ACTION AND CLINICAL PHARMACOLOGY .....................................................................40 STORAGE AND STABILITY ...................................................................................................44 SPECIAL HANDLING INSTRUCTIONS ................................................................................44 DOSAGE FORMS, COMPOSITION AND PACKAGING ......................................................44 PART II: SCIENTIFIC INFORMATION .................................. Read the complete document